The company shared interim results from an ongoing Phase II trial examining its recombinant antibody fusion protein.

AI model transforms heart failure care by precisely identifying cases and enhancing quality evaluations in clinical practice.

Diastolic dysfunction increasingly is recognized as an important cause of congestive heart failure (CHF). In this study, Mayo Clinic researchers surveyed a random sample of 2042 adults (age, 45 or ...

The following is a summary of “Unmasking High-Output Heart Failure: Beyond Conventional Paradigms,” published in the January ...

Chronic heart failure (CHF) is associated with frequent hospitalizations and high mortality. It affects more than 5 million individuals in the USA, and another 660,000 new cases are diagnosed each ...

In the first 22 months of a mavacamten REMS program, few patients needed a temporary interruption in treatment for LVEF below 50%.

The US Food and Drug Administration (FDA) has approved the abbreviated new drug application (ANDA) of Lupin’s Sacubitril and ...

SMALL heart size is linked to higher mortality risk in individuals with normal ejection fraction , particularly in women and those with high-normal ejection fraction.

For technical reasons, the English full text will be published approximately two weeks after the German print edition has been published.

Jan. 22, 2025 — Researchers have developed a way of bioprinting tissues that change shape as a result of cell-generated forces, in the same way that it happens in biological tissues during organ ...

Experts warn that this early stage of heart failure, classified as Stage B, often goes unnoticed but can lead to severe ...

JK-07 is under clinical development by Salubris Biotherapeutics and currently in Phase II for Diastolic Heart Failure (HFpEF). According to GlobalData, Phase II drugs for Diastolic Heart Failure ...